J.P. Morgan 2024: Optimism With An Undercurrent Of Tension

An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.

If the J.P. Morgan Healthcare Conference is a bellwether for the year ahead, 2024 could be on track to be an improvement over 2023 for the biopharma sector. Drug makers, investors and other health care specialists – including more artificial intelligence providers than ever before – descended on San Francisco for the industry’s big annual conference on 8-11 January.

Umbrellas were unfurled throughout the streets around Union Square, as is almost always the case during J.P. Morgan, but this...